Boardroom Alpha
Start trial
Boardroom Alpha
KRRO · Current Report (Form 8-K) · Filed June 11, 2026

Korro Bio Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 11, 2026
Period
Jun 10, 2026
Ticker
KRRO
Accession
0001193125-26-267741
Korro Bio Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Korro Bio stockholders elected two Class I directors, approved executive compensation, and ratified EY.

About Korro Bio Inc
Market cap
$202M
1Y TSR
−33.1%
3Y TSR
−25.4%
Board grade
C-
Sector
Healthcare
CEO
Ram Aiyar
Last annual meeting: Jun 10, 2026 · View full Korro Bio Inc profile →
8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

 

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39062

47-2324450

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

60 First Street, 2nd floor, Suite 250

Cambridge, MA

 

02141

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 468-1999

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

KRRO

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 10, 2026, or the Annual Meeting.

1)
Korro’s stockholders elected each of Nessan Bermingham and Rachel Meyers as Class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2029 and each until his or her respective successor has been duly elected and qualified or until his or her earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the two Class I directors are as follows:

 

Name

 

Votes
For

 

Votes
Withheld

 

Broker
Non-Votes

Nessan Bermingham

 

7,468,003

 

1,576,660

 

1,875,955

Rachel Meyers

 

7,368,284

 

1,676,379

 

1,875,955

 

2)
Korro’s stockholders approved, in a non-binding, advisory vote, the compensation of Korro’s named executive officers. The results of the stockholders’ advisory vote with respect to the compensation of Korro’s named executive officers are as follows:

 

Votes
For

 

Votes
Against

 

Abstain

 

Broker
Non-Votes

9,009,739

 

27,988

 

6,936

 

1,875,955

 

3)
Korro’s stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification are as follows:

 

Votes
For

 

Votes
Against

 

Abstain

 

Broker
Non-Votes

10,917,621

 

2,738

 

259

 

0

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KORRO BIO, INC.

 

 

Date: June 11, 2026

By:

/s/ Ram Aiyar

 

 

 

 

 

Name: Ram Aiyar

 

 

Title: President and Chief Executive Officer and Interim Chief Financial Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings IntelligenceSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Korro Bio Inc (KRRO)

Continue researching
Reference

Frequently asked questions

When did Korro Bio Inc file this 8-K?
Korro Bio Inc (KRRO) filed this Current Report (Form 8-K) with the SEC on June 11, 2026. The accession number assigned by EDGAR is 0001193125-26-267741.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Korro Bio stockholders elected two Class I directors, approved executive compensation, and ratified EY. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Korro Bio Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Korro Bio Inc has filed under CIK 1703647, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer